Cost-effectiveness analysis of influenza vaccination among people aged 50 to 64 in France;Analyse coût-efficacité de la vaccination contre la grippe chez les personnes de 50 à 64 ans en France

Journal d'Economie Medicale

Volumn 24, Issue 6, 2006, Pages 267-285

  Aballea S ^a   Martin, M ^a   Chancellor, J ^a   Carrat, F ^b   Drummond, M ^a,c   Weinstein, M ^d,e  

^a Beaufort House ^*  (United Kingdom)

^b INSERM   (France)

^c i3 Global   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Influenza like illness; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ELDERLY CARE; FLU LIKE SYNDROME; FRANCE; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; TREATMENT OUTCOME;

EID: 33845340504     PISSN: 02940736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Zimmerman RK. Lowering the age for routine influenza vaccination to 50 years: AAFP leads the nation in influenza vaccine policy. American Academy of Family Physicians. Am Fam Physician 1999 Nov 1;60(7):2061-70.
2. st Century: A Tool for Decisionmaking. Washington: National Academy Press ; 2001.
3. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999 Nov;44 Suppl B:11-5.
4. Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996;9 Suppl 3:62-6.
5. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003 May 1;21(16):1769-75.
6. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994 Dec 15;121(12):947-52.
7. Patriarca PA. A randomized controlled trial of influenza vaccine in the elderly. Scientific scrutiny and ethical responsibility. JAMA 1994 Dec 7;272(21):1700-1.
8. Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario's elderly. Can J Public Health 1988 May;79(3):175-80.
9. Nichol KL, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998 Sep 14;158(16):1769-76.
10. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002 Jun 7;20(19-20):2562-78.
11. Das GR, Guest JF. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK. Pharmacoeconomics 2002;20(7):475-84.
12. Leighton L, Williams M, Aubery D, Parker SH. Sickness absence following a campaign of vaccination against influenza in the workplace. Occup Med (Lond) 1996 Apr;46(2):146-50.
13. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995 Oct 5;333(14):889-93.
14. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000 Oct 4;284(13):1655-63.
15. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003 May 16;21(17-18):2216-26.
16. Levy E, Levy P. [Anti-influenza vaccination for active persons (25-64 years): a cost-benefit study]. Rev Epidemiol Sante Publique 1992;40(5): 285-95.
17. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002 Aug 20;137(4):225-31.
18. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999 Sep;5(5):659-71.
19. Millot JL, Aymard M, Bardol A. Reduced efficiency of influenza vaccine in prevention of influenza-like illness in working adults: a 7 month prospective survey in EDF Gaz de France employees, in Rhone-Alpes, 1996-1997. Occup Med (Lond) 2002 Aug;52(5):281-92.
20. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 2005 Sep 21.
21. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006 Jul;31(1):72-9.
22. Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, et al. The Cost Effectiveness of Influenza Vaccination for People aged 50 to 64 years: an International Model. Value Health 2006;in press.
23. Neuzil KM, Reed GW, Mitchel EF, Jr., Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999 Mar 10;281(10):901-7.
24. Aguilera JF, Paget J, Manuguerra JC. Survey of Influenza Surveillance Systems in Europe. European Influenza Surveillance Scheme 2001 December [cited 2006 Sep 18]; Available from: URL: http://www.eiss.org/documents/ inventory_survey.pdf
25. Prior G. Self-reported health. In: Prescott-Clarke P, Primatesta P, editors. Health Survey for England'96. Volume 1: Findings. The Stationery Office; 1998.
26. Collège des Economistes de la Santé. Guide méthodologique pour l'évaluation économique des stratégies de santé. 2003 [cited 2006 Sep 18]; Available from: URL: http://www.ces-asso.org/
27. Lancement de la campagne de vaccination anti-grippale 2004. 2004 September 20 [cited 2005 Jan 25]; Available from: URL: https://www.cnamts.fr/ 174/DOC/1535/cp.html
28. Irwin DE, Weatherby LB, Huang WY, Rosenberg DM, Cook SF, Walker AM. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 2001;1(1):8.
29. Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000 Nov;19(11):834-42.
30. Jimenez R, Larrauri A, Carrasco P, Esteban J, Gomez-Lopez LI, Gil A. Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50-64 years. Vaccine 2003 Sep 8;21(25-26):3550-5.
31. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003 Apr 25;52(RR-8):1-34.
32. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 Jan 8;289(2):179-86.
33. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA 2004 Sep 15;292(11):1333-40.
34. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980 Dec;112(6):798-811.
35. Demicheli V, Rivetti D, Decks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2001;(4):CD001269.
36. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997 May; 39(5):408-14.
37. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999 Jul 14;282(2):137-44.
38. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995 Oct 1;123(7):518-27.
39. Carrat F, Sahler C, Rogez S, Leruez-Ville M, Freymuth F, Le Gales C, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med 2002 Sep 9;162(16):1842-8.
40. Muller D, Saliou P, Szucs TD. [Coverage rates of influenza vaccination in France: a population-based cross-sectional analysis of seasons 2001-2002 and 2002-2003]. Med Mal Infect 2006 Jan;36(1):36-41.
41. Tacken M, Braspenning J, Spreeuwenberg P, van den HH, van Essen G, de Bakker D, et al. Patient characteristics determine differences in the influenza vaccination rate more so than practice features. Prev Med 2002 Oct;35(4):401-6.
42. Public health and aging: influenza vaccination coverage among adults aged > or =50 years and pneumococcal vaccination coverage among adults aged > or = 65 years - United States, 2002. MMWR Morb Mortal Wkly Rep 2003 Oct 17;52(41):987-92.
43. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998 Feb;48(2):85-90.
44. Sessa A, Costa B, Bamfi F, Bettoncelli G, D'Ambrosio G. The incidence, natural history and associated outcomes of influenza- like illness and clinical influenza in Italy. Fam Pract 2001 Dec;18(6):629-34.
45. L'Assurance Maladie en Ligne (AMELI). [cited 2004 Oct 30]; Available from: URL: http://www.ameli.fr
46. Eurostat. Euro-zone labour costs up by 2.5 %. Euro-indicators 2004 Mar 18;41/2004.
47. Paternoster A. Labour Costs Survey 2000. Statistics in Focus 2003 Jun 11;18(Theme 3).
48. OECD. Labour Market Statistics, [cited 2005 Apr 22]; Available from: URL: http://www1.oecd.org/scripts/cde/members/lfsdataauthenticate.asp
49. Programme de Médicalisation des Systèmes d'Information (PMSI). Agence technique de l'information sur l'hospitalisation (ATIH) 2003 [cited 2004 Feb 5]; Available from: URL: http://www.atih.sante.fr/
50. Nomenclature Générale des Actes Professionels (NGAP). Paris : Union des caisses nationales de sécurité sociale (UCANSS); 2003.
51. World Health Organization. Guidelines for estimating costs of introducing new vaccines into the national immunization system. 2002 [cited 2006 Sep 10]; Available from: URL: www.who.int/vaccines-documents/
52. Organisation Mondiale de la Santé. Plan mondial OMS de préparation à une pandémie de grippe. [cited 2005 Dec 20]; Available from: URL: http://www.who.int/csr/resources/publications/influenza/ FluPrep_Fnewweb.pdf
53. Étude permanente de la prescription médicale. 2004. Paris, IMS Health.